Is Upatinib a biological agent? Drug classification analysis

Although Upadacitinib is widely used to treat diseases such as rheumatoid arthritis, psoriatic arthritis and atopic dermatitis, from the perspective of drug classification, it is not a "biological agent" in the traditional sense, but an oral small molecule targeted drug. Its mechanism is mainly through highly selective inhibition of the JAK1 (Janus kinase 1) signaling pathway, thereby interfering with the activity of a variety of pro-inflammatory factors to achieve the purpose of regulating immunity and reducing inflammatory responses.

In medical classification, biological agents usually refer to protein or peptide macromolecular drugs synthesized through biotechnological means (such as genetic engineering, monoclonal antibody technology, etc.). Most of these drugs require injection. Representative examples areTNF-α inhibitors (such as adalimumab) or IL-4/IL-13 targeting antibodies (such as dupilumab). As a small molecule synthetic compound, upadatinib has a clear chemical structure, stable pharmacokinetic characteristics and the convenience of oral use. It should be classified as a "targeted small molecule immunomodulator" or "JAK inhibitor", not a protein or antibody-based biopharmaceutical.

The advantage of upadatinib is that compared with biological agents, it has a more convenient way of taking, a faster onset of action, and the ability to intervene in multiple inflammatory pathways. At the same time, due to its small molecular weight and good tissue penetration, it has certain advantages for patients with deep or extensive tissue inflammation. However, it should be pointed out that although upadatinib itself is not a biological agent, it is often used clinically as a substitute or supplement for similar functions of biological agents, especially when patients have insufficient response to traditional biological agents or an immune reaction.

Reference materials:https://www.rinvoq.com/